Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDICT-RD: Dato-DXd in Early-Stage TNBC With Residual Disease
NCT07069595Phase 2Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Feb 2026
- Primary completion
- Nov 2031
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of datopotamab deruxtecan in triple-negative breast cancer (TNBC), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Feb 2026; status: recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07069595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07069595.